NCT02400476 2022-05-06An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and LoperamidePuma Biotechnology, Inc.Phase 2 Completed563 enrolled 16 charts